{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:22:22Z","timestamp":1761517342036,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[1999,5,1]],"date-time":"1999-05-01T00:00:00Z","timestamp":925516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,5,1]],"date-time":"1999-05-01T00:00:00Z","timestamp":925516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[1999,5]]},"DOI":"10.4158\/ep.5.3.137","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T23:33:41Z","timestamp":1365204821000},"page":"137-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Serious Hypoglycemia Associated With Misuse of Repaglinide"],"prefix":"10.1016","volume":"5","author":[{"given":"Thomas M.","family":"Flood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP.5.3.137_bb0005","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/BF00402171","article-title":"Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells","volume":"38","author":"Gromada","year":"1995","journal-title":"Dlabetologla."},{"key":"10.4158\/EP.5.3.137_bb0010","first-page":"1","article-title":"Prandin a new therapy for type 2 diabetes","volume":"17","author":"Browdows","year":"1998","journal-title":"Practical Dlabetol."},{"key":"10.4158\/EP.5.3.137_bb0015","first-page":"70","article-title":"Repaglinide: a new oral blood glucose-lowering agent","volume":"16","author":"Cheatham","year":"1998","journal-title":"Clin Diabetes."},{"key":"10.4158\/EP.5.3.137_bb0020","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2337\/diacare.18.3.361","article-title":"Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial","volume":"18","author":"Diabetes Control and Complications Trial Research Group (DCCT)","year":"1995","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.5.3.137_bb0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-8529(18)30395-5","article-title":"Drug-induced hypoglycemia: a review of 1418 cases","volume":"18","author":"Seltzer","year":"1989","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.4158\/EP.5.3.137_bb0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2337\/diacare.15.6.737","article-title":"Sulfonylureas in NIDDM","volume":"15","author":"Groop","year":"1992","journal-title":"Diabetes Care."},{"key":"10.4158\/EP.5.3.137_bb0035","first-page":"111","article-title":"Incidence of severe side-effects during therapy with sulfonylureas and biguanides","volume":"15","author":"Berger","year":"1985","journal-title":"Horm Metab Res Suppl."},{"key":"10.4158\/EP.5.3.137_bb0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.279.2.137","article-title":"A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus","volume":"279","author":"Burge","year":"1998","journal-title":"JAMA."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20414028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20414028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/J5DECBQGPF8TWE8N.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:17:20Z","timestamp":1761517040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20414028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,5]]}},"alternative-id":["S1530891X20414028"],"URL":"https:\/\/doi.org\/10.4158\/ep.5.3.137","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[1999,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious Hypoglycemia Associated With Misuse of Repaglinide","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.5.3.137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}